tamsugeni 0.4 mg depotkapseli, kova
biokanol pharma gmbh - tamsulosini hydrochloridum - depotkapseli, kova - 0.4 mg - tamsulosiini
samin 0.4 mg depotkapseli, kova
stichting registratiebeheer - tamsulosini hydrochloridum - depotkapseli, kova - 0.4 mg - tamsulosiini
masulin 0.4 mg depottabletti
sandoz a/s sandoz a/s - tamsulosini hydrochloridum - depottabletti - 0.4 mg - tamsulosiini
duodart 0.5 mg / 0.4 mg kapseli, kova
orifarm oy - tamsulosini hydrochloridum,dutasteridum - kapseli, kova - 0.5 mg / 0.4 mg - tamsulosiini ja dutasteridi
tamsufarm 0.4 mg säädellysti vapauttava kapseli, kova
orifarm oy - tamsulosini hydrochloridum - säädellysti vapauttava kapseli, kova - 0.4 mg - tamsulosiini
omnic ocas 0.4 mg depottabletti
paranova oy - tamsulosin hydrochloride - depottabletti - 0.4 mg - tamsulosiini
omnic ocas 0.4 mg depottabletti
orifarm oy - tamsulosin hydrochloride - depottabletti - 0.4 mg - tamsulosiini
adcirca (previously tadalafil lilly)
eli lilly nederland b.v. - tadalafil - hypertensio, keuhkokuume - urologiset - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. tehoa on osoitettu idiopaattisessa pah: ssa (ipah) ja pah: ssa, joka liittyy kollageenin verisuonisairauteen. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.
urorec
recordati ireland ltd - silodosiinilla - prostatic hyperplasia - urologiset - hyvänlaatuisen eturauhasen liikakasvun (bph) merkkien ja oireiden hoito.